Urovant Sciences, Holly Robinson Peete raise awareness for overactive bladders

Urovant Sciences, a subsidiary of Sumitovant Biopharma, and makers of Gemtesa are partnering with actress and overactive bladder patient Holly Robinson Peete as part of its “Time To Go” campaign — an educational program to raise awareness of OAB.

The company described the campaign as one which aims to highlight the impact the condition can have on patients and introduce options for managing symptoms of OAB, which may make those living with the condition feel more comfortable seeking help from their healthcare provider.

OAB causes sudden urges to urinate that are difficult to control and can result in leakage, as well as frequent urination — usually eight or more times a day. Approximately 33 million Americans experience bothersome bladder symptoms — and the prevalence increases with age. These symptoms can negatively impact daily activities such as changing travel plans, exercising less or not at all and limiting certain activities, the company said.

[Read more: Camber debuts generic Vesicare]

“I experienced OAB symptoms for years prior to talking to my doctor about potential treatment options, and I wish I had sooner,” said Peete. “I noticed I was going to the bathroom a lot and had a sudden urge to go, like now. With my OAB symptoms, there was a lot of added stress and worry before I traveled either for work or for fun. I’ve seen a positive impact on my OAB symptoms with Gemtesa. By reducing my symptoms, I’m spending my time planning activities and less time mapping out the closest bathroom.”

Research shows that many people with symptoms of OAB delay seeking help from their doctors. On average, patients waited 3.5 years between noticing OAB symptoms and seeking a doctor’s help. This may be because they are too embarrassed to discuss their symptoms or mistakenly think it’s just a normal part of aging, the company said.

“We’re excited to work with Holly Robinson Peete to raise awareness about OAB and help reduce the stigma around the condition,” said James Robinson, CEO of Urovant. “We believe this collaboration will bring more attention to recognizing its symptoms and the treatment options that may help.”